Fidelity Investments’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-70,653
| Closed | -$1.37M | – | 5803 |
|
|
2024
Q4 | $1.37M | Hold |
70,653
| – | – | ﹤0.01% | 2564 |
|
|
2024
Q3 | $1.11M | Hold |
70,653
| – | – | ﹤0.01% | 2565 |
|
|
2024
Q2 | $597K | Sell |
70,653
-2
| -0% | -$23 | ﹤0.01% | 2667 |
|
|
2024
Q1 | $1.09M | Hold |
70,655
| – | – | ﹤0.01% | 2481 |
|
|
2023
Q4 | $975K | Buy |
70,655
+1
| +0% | +$12 | ﹤0.01% | 2480 |
|
|
2023
Q3 | $808K | Sell |
70,654
-7
| -0% | -$130 | ﹤0.01% | 2503 |
|
|
2023
Q2 | $1.76M | Sell |
70,661
-76
| -0.1% | -$2.23K | ﹤0.01% | 2354 |
|
|
2023
Q1 | $2.57M | Sell |
70,737
-162
| -0.2% | -$9.93K | ﹤0.01% | 2305 |
|
|
2022
Q4 | $4.28M | Buy |
70,899
+139
| +0.2% | +$9.32K | ﹤0.01% | 2164 |
|
|
2022
Q3 | $5.31M | Buy |
70,760
+22
| +0% | +$2.3K | ﹤0.01% | 2150 |
|
|
2022
Q2 | $8.11M | Sell |
70,738
-117
| -0.2% | -$13.7K | ﹤0.01% | 2065 |
|
|
2022
Q1 | $13.4M | Buy |
70,855
+201
| +0.3% | +$46.5K | ﹤0.01% | 1996 |
|
|
2021
Q4 | $24.5M | Hold |
70,654
| – | – | ﹤0.01% | 1735 |
|
|
2021
Q3 | $23.7M | Hold |
70,654
| – | – | ﹤0.01% | 1760 |
|
|
2021
Q2 | $58.2M | Buy |
+70,654
| New | +$54.8M | ﹤0.01% | 1363 |
|
Fidelity Investments's OMIC Position: Q1 2025 in Review
Fidelity Investments sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q1 2025, closing a stake of 70,653 shares — an estimated $1.37M sold.
Fidelity Investments first reported a position in OMIC in Q2 2021 and held it in 15 quarters. The position peaked at $58.2M in Q2 2021. 0 funds tracked by Wall St. Rank hold OMIC as of Q1 2025.
- Fidelity Investments reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Fidelity Investments sold 70,653 Singular Genomics Systems, Inc. Common Stock shares in Q1 2025, an estimated $1.37M.
- Fidelity Investments first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 15 quarters.
- Fidelity Investments's Singular Genomics Systems, Inc. Common Stock position peaked at $58.2M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q1 2025.
Based on Fidelity Investments's 13F filing for Q1 2025, filed 12 May 2025.